Showing 231-240 of 333 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Role of β-cell Golgi dysfunction in Type 1 diabetes pathogenesis | The University of Iowa | Samuel Stephens | Cures | 01-June-2024 to 31-May-2027 | $750,000.00 |
| The Development of 3-β-hydroxybutyrate binding protein based electrochemical micro-sensor and its application for CKM system | The University of North Carolina at Chapel Hill | Koji Sode | Improving Lives | 01-October-2022 to 30-September-2025 | $799,999.96 |
| GABP regulation of human beta cell proliferation | The University of Texas Health Science Center at Houston | Richard Cox | Cures | 01-September-2024 to 31-August-2026 | $200,000.00 |
| Development of Low Cost, High Precision Nano Pumps for Insulin Delivery | Torramics Inc. | Sergey Gimelshein | Improving Lives | 01-March-2023 to 31-August-2025 | $1,493,212.43 |
| Achieving persistent presentation of self-antigens to reestablish tolerance and prevent autoimmune diabetes | Trustees of Columbia University in the City of New York | Camillo Bechi Genzano | Cures | 01-March-2025 to 29-February-2028 | $256,285.00 |
| Improving pig islet transplant efficacy in a preclinical baboon diabetes model with induced immune tolerance to the xenografts | Trustees of Columbia University in the City of New York | Megan Sykes | Cures | 01-June-2024 to 31-May-2026 | $599,999.94 |
| In vivo analysis of human islet graft infiltration and its immunomodulation by antigen-specific therapy | Trustees of Columbia University in the City of New York | Remi Creusot | Cures | 01-August-2022 to 31-July-2025 | $699,997.82 |
| Low level engraftment of modified HSCs for continuous and omnipresent autoantigen exposure as requirements to establish tolerance | Trustees of Columbia University in the City of New York | Remi Creusot | Cures | 01-June-2024 to 31-January-2026 | $188,704.16 |
| Evaluation of Oxidized Insulin as a Biomarker and Therapeutic Target in Type 1 Diabetes | Trustees of Indiana University | Amelia Linnemann | Cures | 01-October-2023 to 30-September-2025 | $560,000.00 |
| Defining the role of islet-derived extracellular vesicle PD-L1 cargo in type-1 diabetes | Trustees of Indiana University | Chaitra Rao | Cures | 01-March-2024 to 30-April-2027 | $228,537.45 |